GSK Cuts U.S. Sales Reps To Gain Greater Share Of China, India Markets
This article was originally published in PharmAsia News
Executive Summary
The U.K.'s GlaxoSmithKline is using a reduction of 1,000 sales jobs in the United States to enhance its expansion plans in China and India. The company said it would lay off the sales reps by the end of the year. CEO Andrew Witty said the company sees a huge future in emerging markets of the East where partnerships are available for marketing branded drugs. Witty's interest in the China market dates back to 2000-2002 when he served as economic adviser to the governor of a Chinese province. (Click here for more